Drugs / WN/DEN4Δ30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02186626 | Feb 2014 → Jul 2016 | Flaviviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WN/DEN4Δ30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02186626 ↗ |
| Modality | Vaccine | “WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus.” NCT02186626 ↗ |
| Route | Subcutaneous | “delivered by subcutaneous injection in the deltoid region of the upper arm.” NCT02186626 ↗ |